LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

18.17 -1.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.73

Máximo

18.52

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	503
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+92.86% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	159M 3.1B
Abertura anterior	19.31
Fecho anterior	18.17

Sentimento de Notícias

By Acuity

50%

157 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

13.355 / 16.44 Suporte e Resistência

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de mai. de 2026, 23:10 UTC

Ações em Alta

Stocks to Watch: Agilysys, XP

18 de mai. de 2026, 18:44 UTC

Grandes Movimentos do Mercado

Claritev Shares Recover After Comments About DOJ

18 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 de mai. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

18 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

18 de mai. de 2026, 20:25 UTC

Ganhos

Correct: XP 1Q Total Client Assets BRL1.53T

18 de mai. de 2026, 20:23 UTC

Ganhos

XP 1Q Total Client Assets BRL1.53B

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Adj EPS BRL2.49 >XP

18 de mai. de 2026, 20:19 UTC

Ganhos

XP 1Q Rev BRL4.73B >XP

18 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 de mai. de 2026, 19:00 UTC

Ganhos

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 de mai. de 2026, 18:52 UTC

Conversa de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 de mai. de 2026, 18:17 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 de mai. de 2026, 17:22 UTC

Conversa de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 de mai. de 2026, 16:57 UTC

Aquisições, Fusões, Aquisições de Empresas

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

18 de mai. de 2026, 16:57 UTC

Conversa de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 de mai. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Doesn't Set Out Financial Details of Deal

18 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 de mai. de 2026, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 de mai. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Vinci Buys Canada's Modern Group of Companies

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

92.86% parte superior

Previsão para 12 meses

Média 35.91 USD 92.86%

Máximo 42 USD

Mínimo 23 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimento

By Acuity

157 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.